Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer

Chanchan Gao; Xuyu Gu; Yan Chen; Min Zhou; Feng Jiang; Shiya Zheng

doi:10.12659/MSM.932275

01 November 2021 : Database Analysis

Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer

Chanchan Gao^1E, Xuyu Gu^1A*, Yan Chen^1C, Min Zhou^1D, Feng Jiang^1F, Shiya Zheng^1G

DOI: 10.12659/MSM.932275

Med Sci Monit 2021; 27:e932275

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 5 Assessment for chemotherapeutic responses to cisplatin and etoposide. (A) The estimated IC50 of cisplatin and etoposide to MCM-2. (B) The estimated IC50 of cisplatin and etoposide to EZH2. (C) The estimated IC50 of cisplatin and etoposide to CDKN2A. (D) The estimated IC50 of cisplatin and etoposide to CENPK. (E) The estimated IC50 of cisplatin and etoposide to CHEK1. (F) The estimated IC50 of cisplatin and etoposide to EXOSC2. (R software [Version 4.0.0, http://www.r-project.org]).

Back to the Article

Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer

Your Privacy